Professor David Wynick

B.Sc., MBBS, M.D.(Lond.), Ph.D.(Open), F.R.C.P.

  • BS2 8AE

19982018

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Neuropathic pain (NP) affects about 8% of the people in the Western World and the commonest cause is diabetes mellitus. NP places an enormous emotional and financial burden on patients, carers and society. Very few NP patients obtain complete pain relief with the currently available drugs and more effective long-term therapies are urgently required. My basic-science and clinical research is focused on better understanding the mechanisms that underlie the development and maintenance of NP.

Over the last 20 years my group has identified and validated the second galanin receptor (GalR2) as a novel treatment for NP. I am now translating these findings into pre-clinical drug development for neuropathic pain by developing novel GalR2-specific ligands with the longer-term aim of taking ligands into proof-of-concept clinical studies for the treatment of painful diabetic neuropathy (PDN).

My clinical research is based on the regional PDN out-patient service I setup and run (2009-present). I see patients with complex severe refractory PDN from across the SW of England. 

Fingerprint Dive into the research topics where David Wynick is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Projects

Research Output

  • 62 Article (Academic Journal)
  • 2 Chapter in a book

Targeted disruption of the orphan receptor Gpr151 does not alter pain-related behaviour despite a strong induction in dorsal root ganglion expression in a model of neuropathic pain

Holmes, F. E., Kerr, N. C. H., Vanderplank, P. A., McArdle, C. & Wynick, D., 1 Jan 2017, In : Molecular and Cellular Neuroscience. 78, p. 35-40 6 p.

Research output: Contribution to journalArticle (Academic Journal)

Open Access
File
  • 8 Citations (Scopus)
    314 Downloads (Pure)

    Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor

    Gresle, M. M., Butzkueven, H., Perreau, V. M., Jonas, A., Xiao, J., Thiem, S., Holmes, F. E., Doherty, W., Soo, P-Y., Binder, M. D., Akkermann, R., Jokubaitis, V. G., Cate, H. S., Marriott, M. P., Gundlach, A. L., Wynick, D. & Kilpatrick, T. J., Jun 2015, In : Glia. 63, 6, p. 1005-1020 16 p.

    Research output: Contribution to journalArticle (Academic Journal)

    Open Access
    File
  • 7 Citations (Scopus)
    301 Downloads (Pure)

    Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity

    Lang, R., Gundlach, A. L., Holmes, F. E., Hobson, S., Wynick, D., Hökfelt, T. & Kofler, B., Jan 2015, In : Pharmacological Reviews. 67, 1, p. 118-175 58 p.

    Research output: Contribution to journalArticle (Academic Journal)

    Open Access
    File
  • 149 Citations (Scopus)
    424 Downloads (Pure)